Colorectal Cancer Metastatic, Thromboembolism
Conditions
Keywords
LMWH, Prophylaxis, Thromboembolic event, Colorectal cancer
Brief summary
Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population. PROTINCOL is a randomized, open label, non placebo-controlled, low intervention, and phase III clinical trial that will recruit patients with mCRC. The study hypothesizes that prophylaxis with Tinzaparin could prevent the appearance of symptomatic and incidental VTE. All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria. Enrolled patients are randomized in a 1:1 ratio (stratifying by BRAF/RAS, resection of primary tumor, and anti-angiogenic first-line treatment) to: control arm (no interventions related to VTE risk and no placebo) or experimental arm (prophylactic Tinzaparin at a fixed dose of 4500 IU/day in patients with up to 80kg, 6000 IU/day for those between 80-100 kg, or 8000 IU/day for those \>100kg). Treatment is scheduled for a maximum period of 4 months. Treatment could be stopped earlier in case of unacceptable toxicity, patient consent withdrawal, physician criteria or end of study. Patients will undergo tumor and VTE assessments according to standard clinical practice. The main objective of the study is to evaluate the efficacy of tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary objectives include the associations between VTE events and tumor characteristics (i.e. laterality, RAS/BRAF mutations) or management (i.e. surgery or treatment with anti-angiogenic or anti-EGFR agents), cancer-specific survival outcomes, safety, the incidence of bleeding events, and patient-reported quality of life. The trial includes also a translational exploratory analysis to assess the predictive value of risk assessment models and genetic risk scores, their evolution through the study and microsatellite instability or other biomarkers.
Detailed description
This research study is a prospective, randomized, open label (PROBE), non placebo-controlled, and phase III clinical trial; Investigator Initiated Study (IIS). The study has been considered a low-interventional clinical trial. The trial will compare the efficacy and safety of tinzaparin with a watch and wait strategy for primary prophylaxis of symptomatic or incidental VTE in adult men and women, 18 years of age and older, with metastatic colorectal cancer who are scheduled to initiate systemic cancer therapy as a component of their standard of care anticancer regimen. The study consists of 3 periods: a 4-week screening period, a 4 months treatment period and post-treatment follow-up period until the end of treatment (EOT) visit, scheduled 2 months after the last dose of tinzaparin or 6 months from the first dose of tinzaparin (whichever occurs latest). The duration of participation in the study for each subject is approximately 6 months. Further long-term phone follow-up to monitor for progression and survival could be carried out at the end of study. Tumor follow-up assessments will adhere to the standard clinical practice within each site. All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria and current guideline recommendations. Patients in both groups will receive supportive care as per local practice. No formal recommendations will be issued by the study protocol regarding cancer treatment and supportive care, but the drugs used will be recorded in the clinical report form. Constitutive use of anticoagulant drugs will be prohibited during the treatment period. Enrolled patients are randomized in a 1:1 ratio to the control arm, or the experimental arm: Control arm: A watch and wait strategy will be used. There is no placebo. Since no reference treatment is available for long-term VTE prophylaxis in patients with cancer, patients in the control group will not receive VTE prophylaxis outside the hospital and will receive anticancer treatment and supportive care as per local practice. No formal recommendations will be issued by the study protocol regarding cancer treatment and supportive care, but the drugs used will be recorded in the clinical report form (CRF). Patients in the control group will receive antithrombotic prophylaxis as per local practice during hospitalizations. Any use of LMWH will be recorded in the CRF. Experimental arm: Patients will receive prophylaxis tinzaparin at a fixed dose daily for 4 months. The primary objective is to evaluate the efficacy of 4-months prophylaxis with tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary efficacy objectives include the VTE incidence in specific subpopulations (stratification according to the laterality of the primary tumor, first-line treatment with anti-EGFR or antiangiogenics, and mutational status). Safety of tinzaparin will be evaluated by means of relevant adverse events, incidence of bleedings according to International Society of Thrombosis and Hemostasis (ISTH) criteria, and patient-reported quality of life. Bleeding events will be evaluated locally by the investigator and centrally by a blinded committee.
Interventions
DRUGTinzaparin
Patients \< 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients \> 100 kg will receive a fixed dose of 8000 IU daily.
Sponsors
LEO Pharma
Galician Research Group on Digestive Tumors
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Two-arm, randomized, non-placebo controlled, open-label
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects with age ≥ 18 years. 2. Written informed consent. 3. Patients with a histologically confirmed diagnosis of stage IV colon or rectal adenocarcinoma (mCRC). 4. Locally assessed BRAF and RAS genomic alterations available during screening. 5. Beginning of the first line of treatment for metastatic disease with chemotherapy +/- targeted therapy (i.e. antiangiogenic, anti-EGFR, encorafenib-cetuximab doublet) or immunotherapy. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Life expectancy \>6 months.
Exclusion criteria
1. Contraindication to tinzaparin, or other heparins: 1. Allergy (or hypersensitivity) to heparin, tinzaparin, other LMWHs, or pork products. 2. History or presence of heparin-induced (type II) thrombocytopenia. 3. Have or have had an epidural catheter or a traumatic spinal puncture within the previous 7 days. 2. Prothrombin time (PT) (International normalized ratio \[INR\] \>1.5 for any reason) or aPTT \>2 times control value. 3. Active major bleeding or conditions predisposing to major bleeding. a major bleeding is defined as one that meets one of the following three criteria: 1. occurring in a critical area or organ (for example, intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular or pericardial, intrauterine or intramuscular with compartment syndrome), 2. causing a decrease in hemoglobin levels of 2 g/l (1.24 mmol/l) or more, or that requires a transfusion of two or more units of whole blood or packed red blood cells. 4. Lesions or conditions at increased risk of clinically significant bleeding, including: 1. Previously diagnosed/treated VTE ≤ 28 days prior to randomization. 2. Active ulcer disease. 3. Diagnosed cerebral metastases. 4. Stroke within the prior 6 months. 5. History of central nervous system (CNS) or intraocular bleeding. 5. Requirement of other anticoagulant therapy, dual antiplatelet therapy, daily non-steroidal anti-inflammatory drugs, or other medications known to increase the risk of bleeding. Note: A daily dose of ≤100 mg of aspirin and single agent clopidogrel are permitted 6. Acute or chronic renal insufficiency with Creatinine clearance \< 30 ml / min. 7. Platelet count \< 80.000 /ml at the time of inclusion. 8. Severe liver insufficiency as defined by clinical manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or biochemical abnormalities in liver function tests including: 1. elevated levels of total bilirubin (\> 2 times the upper limit normal \[ULN\]), 2. elevated liver transaminases (\> 2 times the ULN; \> 5 in case of hepatic metastasis). 9. Participating in another study of an investigational agent at the time of enrollment. Note: Use of an experimental regimen of an approved product is not cause for exclusion. 10. Patients who weigh \< 50 Kg. 11. Women of childbearing potential (WOCBP), must provide a negative serum or urine pregnancy test at screening. Women breastfeeding are not eligible. Note: A pregnancy test is performed on WOCBP as per standard of care for patients undergoing anticancer treatments. 12. Any underlying medical or psychiatric disorder, which, in the opinion of the investigator, makes the administration of tinzaparin unsafe or interferes with the informed consent process or trial procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of any VTE | Throughout the study period, approximately 6 months per patient | The primary efficacy endpoint is the cumulative incidence (percentage of patients) of any VTE event including: Symptomatic non-fatal pulmonary thromboembolism (PE). Symptomatic lower-limb deep vein thromboembolism (sllDVT). Symptomatic upper extremity deep vein thromboembolism (sueDVT). Incidentally diagnosed PE or proximal DVT. Symptomatic central venous catheter thromboembolism. Incidentally visceral vein thrombosis (iVVT). Symptomatic visceral vein thrombosis (sVVT). VTE-related deaths |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of symptomatic non-fatal PE | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of sllDVT | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of sueDVT | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of incidentally diagnosed PE or proximal DVT | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of symptomatic central venous catheter thromboembolism | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of iVVT | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of sVVT | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of VTE-related deaths | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing the event during the observation period (6 months) |
| Incidence of confirmed VTE events in BRAF/RAS mutated patients | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients with BRAF / RAS tumor genomic mutations vs native BRAF / RAS tumors. |
| Incidence of confirmed VTE events in resected or not resected patients | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients with primary tumor resection vs not resection. |
| Incidence of confirmed VTE events in patients with antiangiogenic therapy | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients on antiangiogenic treatment |
| Incidence of confirmed VTE events in patients with anti-EGFR therapy | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients on anti-EGFR treatment |
| Incidence of confirmed VTE events in patients according to progression (PD) | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients with PD according to usual clinical practice determined by the treating physician during treatment with tinzaparin |
| Incidence of confirmed VTE events in patients according genetic risk scores | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients according to their genetic risk score |
| Incidence of confirmed VTE events in patients according to blood type | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients according to their blood type |
| Incidence of arterial thromboembolic events (ATE) | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing ATE |
| Incidence of confirmed VTE events in patients according to tumor laterality | Throughout the study period, approximately 6 months per patient | Percentage of patients experiencing confirmed VTE events in patients with right-side / transverse primary tumor vs left-side primary tumor. |
| Event-free survival (EFS) | Throughout the study period, approximately 6 months per patient | Events are defined as the endpoint of mortality, major bleeding and VTE. EFS is defined as the time elapsed from the first dose of study treatment to the diagnosis of VTE event, major bleeding event, or death by any cause, whichever occurs first |
| Progression-free survival (PFS) | Throughout the study period, approximately 6 months per patient | Defined as the time elapsed from the first dose of study treatment to progression determined by the treating physician according to local standard clinical practice, or death from any cause, whichever occurs first |
| Overall survival (OS) | Throughout the study period, approximately 6 months per patient | Defined as the time elapsed from the first dose of study treatment until death from any cause |
| Mortality rate | Throughout the study period, approximately 2 years | Percentage of patients who died through the study |
| Incidence of relevant adverse events (AE) | Throughout the study period, approximately 2 years | Percentage of patients who experience grade 3-5 according to CTCAE version 5.0 |
| Incidence of treatment-related AEs (TRAEs) | Throughout the study period, approximately 2 years | Percentage of patients who experience TRAEs |
| Incidence of major bleeding (MB) events | Throughout the study period, approximately 6 months per patient | Percentage of patients who experience MB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment |
| Incidence of Clinically relevant non-major bleeding (CRNMB) | Throughout the study period, approximately 6 months per patient | Percentage of patients who experience CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment |
| Quality of life score | Throughout the study period, approximately 6 months per patient | Patients reported outcomes through the EORTC quality of life questionnaire (QLQ)-C30 questionnaire. QLQ-C30 scale is a 28 items that are scored on a 4-point response scale. All scale scores are linearly converted to range from 0 to 100. For the functioning scales and global QOL higher scores indicate better functioning. |
| Incidence of bleeding events in BRAF/RAS mutated patients | Throughout the study period, approximately 6 months per patient | Percentage of patients who experienced a MB or CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment. Results will be reported according to BRAF/RAS mutational statu |
| Incidence of bleeding events according to surgery | Throughout the study period, approximately 6 months per patient | Percentage of patients who experienced a MB or CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment. Results will be reported according to previous surgery of the primary tumor |
| Incidence of bleeding events according to antiangiogenic therapy | Throughout the study period, approximately 6 months per patient | Percentage of patients who experienced a MB or CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment. Results will be reported according to first-line antiangiogenic agents treatment |
| Incidence of bleeding events according to anti-EGFR therapy | Throughout the study period, approximately 6 months per patient | Percentage of patients who experienced a MB or CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment. Results will be reported according to first-line anti-EGFR treatment |
| Incidence of bleeding events according to tumor laterality | Throughout the study period, approximately 6 months per patient | Percentage of patients who experienced a MB or CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment. Results will be reported in patients with right-sided or transversal vs. left-sided primary tumor |
| Incidence of bleeding events according to genetic risk | Throughout the study period, approximately 6 months per patient | Percentage of patients who experienced a MB or CRNMB according to ISTH criteria throughout the study period and up to month 2 of end of tinzaparin treatment. Results will be reported in patients according to their genetic risk score |
| Thrombosis-free survival (TFS) | Throughout the study period, approximately 6 months per patient | Defined as the time elapsed from the first dose of study treatment to the diagnosis of thrombotic event, or death from any cause, whichever occurs first |
Countries
Spain
Outcome results
None listed